Shared Decision-Making in Cervical Cancer

Gentle movement during cancer treatment can help maintain strength, mobility and balance. Follow Jennifer Tipton’s simple exercises to keep your body moving.

At three years, 69% of patients treated with Imfinzi and chemotherapy around surgery were alive, compared with 62% of patients treated with chemotherapy alone.

Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.

A reflection on shame, vulnerability and transformation, exploring how the past shapes us and how presence can help us let go and heal.

Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.

AJ Wyman shares his daughter’s cancer journey and why parents caring for a child with cancer must make time for their own mental health, too.

A powerful reflection on finding hope, healing and meaning through life’s challenges, inspired by the lessons and beauty found in the sea.

In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went a median of 14.3 months without their disease worsening, compared with 8.3 months with immunotherapy plus chemotherapy.